钠-葡萄糖协同转运蛋白2抑制剂治疗心力衰竭的临床研究进展  

Clinical progress of Sodium glucose Cotransporter 2 inhibitors in the treatment of heart failure

作　　者：曹楠 罗勇[1] CAO Nan;LUO Yong(North Sichuan Medical College,Nanchong,Sichuan 637000,China)

机构地区：[1]川北医学院,四川南充637000

出　　处：《医药前沿》2021年第27期24-26,共3页Journal of Frontiers of Medicine

摘　　要：心力衰竭是各种心脏疾病的严重表现或晚期阶段,病死率和再住院率始终居高不下。钠-葡萄糖协同转运蛋白2抑制剂作为一种新型口服降糖药物,由于其降糖作用外潜在的心血管获益作用,为心力衰竭的治疗提供了新的方向,本文就钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭治疗中的最新研究进展进行综述,为心力衰竭的治疗提供新的思路。Heart failure is a serious manifestation or late stage of various heart diseases,and the rate of mortality and rehospitalization remain high.As a new oral hypoglycemic drug,Sodium-glucose Cotransporter 2 inhibitors provides a new therapeutic direction for heart failure due to its potential cardiovascular benefits in addition to hypoglycemic effect.This review describes the latest research progress of Sodium-glucose Cotransporter 2 inhibitors in the treatment of heart failure and provides a new idea for the treatment of heart failure.

关 键 词：心力衰竭 钠-葡萄糖协同转运蛋白2 钠-葡萄糖协同转运蛋白2抑制剂 

分 类 号：R541.6[医药卫生—心血管疾病]